What Is Adoptive Cell Therapy? A Beginner's Guide to CAR-T, TIL, and NK Cell Treatments

What This Article Covers

If you've heard the term “CAR-T” and assumed it was the whole story of cell therapy, you're not alone — but it's actually one branch of a larger family called adoptive cell therapy (ACT). This article breaks down what ACT means as an umbrella term, how its four major approaches (CAR-T, TIL, CAR-NK, and TCR-engineered T-cells) differ mechanistically, which are actually FDA-approved today versus still experimental, and what the real, sourced data says about how well they work — and what they still can't do.

The Basic Idea Behind Adoptive Cell Therapy

Adoptive cell therapy is not a single drug — it's a strategy. In every version of it, immune cells are collected from a patient (or occasionally a donor), taken outside the body, modified and/or multiplied in a lab, and then infused back to fight cancer. The idea has been studied since the 1980s, when researchers first tried expanding a patient's own tumor-fighting white blood cells and reinfusing them. What's changed since then is genetic engineering: scientists can now redesign a patient's immune cells before growing them, giving them new “eyes” to spot cancer cells they would otherwise miss. According to the National Cancer Institute, the CAR-T manufacturing process — collection, engineering, expansion, and infusion — typically takes about three to five weeks from blood draw to the finished product going back in. That timeline is one reason ACT is generally reserved for patients whose disease, and overall health, can wait out the process.

CAR-T: Engineering T-Cells to Find Cancer

CAR-T (chimeric antigen receptor T-cell) therapy is the most established form of ACT and the one most people mean when they say “cell therapy.” T cells — the immune system's frontline killers — are removed from the patient's blood and genetically engineered to express a synthetic receptor, the CAR, on their surface. This receptor is designed to latch onto a specific protein found on cancer cells, most commonly CD19 (a marker on B cells, and therefore B-cell leukemias and lymphomas) or BCMA (a marker on the plasma cells behind multiple myeloma). Once the CAR locks onto its target, the T cell activates and kills the cancer cell directly, then multiplies to hunt down more. Before the engineered cells go back in, patients typically receive lymphodepleting chemotherapy to clear out competing immune cells and make room for the new ones to expand.

TIL Therapy: Using the Patient's Own Tumor-Fighting Cells

Tumor-infiltrating lymphocyte (TIL) therapy takes a different route to the same goal. Instead of engineering a receptor from scratch, doctors surgically remove a piece of the patient's tumor and extract the T cells already living inside it — cells that have, in effect, already been “trained” by the body to recognize that specific cancer, even if too few were present to control it alone. Those cells are then multiplied by the billions in the lab over several weeks and infused back, again after lymphodepleting chemotherapy. Because TIL therapy relies on cells the immune system selected naturally rather than one engineered receptor, it doesn't require a known, uniform surface target the way CAR-T does — part of why it has shown promise in solid tumors like melanoma, where CAR-T has largely struggled.

CAR-NK and What's on the Horizon

CAR-NK therapy applies the same engineering logic as CAR-T, but to natural killer (NK) cells instead. NK cells are part of the innate immune system and are built to kill abnormal cells on contact, without needing to be “taught” to recognize a target first; giving them a CAR sharpens that targeting further. Researchers are especially interested in CAR-NK because NK cells appear less likely to cause the severe side effects seen with CAR-T, and — unlike a patient's own T cells — NK cells from healthy donors may be usable in multiple patients as an “off-the-shelf” product, potentially cutting the manufacturing wait. A related approach, TCR (T-cell receptor)-engineered T-cell therapy, re-engineers T cells' natural receptors rather than bolting on a synthetic CAR, allowing recognition of protein fragments displayed from inside a cancer cell, not just on its surface.

What's Actually Approved Today vs. Still Investigational

As of this writing, seven CAR-T products have FDA approval, all for blood cancers: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl, covering various forms of leukemia, lymphoma, and multiple myeloma. The data behind them can be striking — in the ZUMA-12 trial of Yescarta as a first-line treatment for high-risk large B-cell lymphoma, 78% of patients achieved a complete response, meaning no detectable cancer remained on scans. TIL therapy crossed into approved territory in February 2024, when the FDA approved Amtagvi (lifileucel) for advanced melanoma that had already progressed on other immunotherapy — the first approved cell therapy of its kind, with a 31.5% objective response rate. TCR-engineered T-cell therapy also has one approved entry: Tecelra (afamitresgene autoleucel), cleared in August 2024 for metastatic synovial sarcoma, a rare soft-tissue cancer, based on a trial in which tumors shrank in 43% of patients. CAR-NK therapy, by contrast, remains entirely investigational — no CAR-NK product has FDA approval, and all current use is through clinical trials.

Bottom Line

Adoptive cell therapy has moved from a research concept to a genuine treatment category in a little over a decade, and the results in certain blood cancers — durable complete remissions in patients who had run out of other options — are among the most encouraging in modern oncology. But the field is still young and uneven: CAR-T and TIL therapy carry real risks, including cytokine release syndrome (CRS) and neurotoxicity (ICANS), both requiring specialized medical centers to manage safely; manufacturing takes weeks and costs hundreds of thousands of dollars, limiting access; and outside melanoma and synovial sarcoma, solid tumors have so far resisted these approaches far more than blood cancers have. CAR-NK and most TCR-T applications remain investigational, meaning any current use outside a clinical trial should raise real questions. The honest picture is one of genuine, hard-won progress in a handful of cancers, with much broader ambitions still being tested.